🏢 公司NewsroomIDYAQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 09-01(美西日)仅日期·时区推断·⟳ 抓取 18:36:12·⚡ 决策 09-01 18:37:23 +1m11s·56.2 天前
IDEAYA Biosciences宣布11月伦敦投资者研发日及9月多场投资者会议参会安排
这是一份标准的投资者关系日程公告，仅列出未来数周的会议参会安排和11月的研发日计划。公告不含任何新临床数据、监管决定、商业合作、财务指引变化或其他可改变公司估值的新增事实。唯一提到的'新临床前数据'将在2026年11月16日才披露，距当前超过2个月，不构成当前可交易催化。
📄 原文IDYA↗ 原文
SOUTH SAN FRANCISCO, Calif. , Sept. 1, 2026 / PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medi…
不做 IDEAYA Biosciences（IDYA.US）
纯IR日程公告（会议参会安排+未来研发日预告），不含任何新增实质事实（无临床数据、无监管进展、无商业合作、无财务变化），不构成可交易催化。研发日新数据披露在2026年11月16日，届时再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IDEAYA于2026年9月1日发布IR日程公告，宣布参加9月四场投资者会议火边对话及11月16日伦敦研发日。公告内容为纯日程安排，无新数据、无交易、无监管进展。研发日提及的'新临床前数据'属前瞻性描述，实际披露在2个半月后。此类公告对股价无增量信息影响，不构成任何方向的交易催化。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例——事件本身不构成可交易催化
原文全文
展开原文 · 4,415 字
SOUTH SAN FRANCISCO, Calif.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。